AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on March 23, 2022. The company is a Delaware corporation with its principal executive offices in Englewood, Colorado. Its common stock trades on The NASDAQ Stock Market LLC under the symbol "AYTU".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure event rather than financial performance data.
Material Changes and Events
Under Item 7.01 (Regulation FD Disclosure), the Company announced that its newly issued U.S. Patent No. 11,166,947 for Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablet has been listed in the U.S. Food and Drug Administration (FDA) publication, "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the "Orange Book."
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard regulatory context of the patent listing. The press release attached as Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the listing of U.S. Patent No. 11,166,947 in the FDA Orange Book for Cotempla XR-ODT.
- Confirm the implications of the Orange Book listing on potential generic competition timelines.
- Review the attached press release (Exhibit 99.1) for additional details not included in the 8-K text.